retatrutide clinical trials review Retatrutide, an experimental drug currently in Phase 3 trials, is nicknamed the Godzilla of weight-loss jabs because of its potential superior efficacy. Developed by Eli Lilly, is a triple hormone Retatrutide—A Game Changer in Obesity

Noom program features comparison (2026) Each Noom program supports sustainable weight loss, but they differ in the type of support they offer

Individual Risk Factors and Personalization for GLP-1 Tolerability Genetic variation in GLP-1 receptor signaling, inflammatory response pathways, and metabolic adaptation capacity influence how your body tolerates semaglutide

I encourage maintaining at least 1,200 calories for women and 1,500 for men even when appetite permits less

In a recent trial studying the effectiveness of tirzepatide (Zepbound) for weight loss, participants lost an average of 20.9% of their body weight at 36 weeks